Insulin-like growth factor receptor-1 expression predicts postoperative recurrence in adenocarcinoma of the lung

Nakagawa,Makoto; Uramoto,Hidetaka; Shimokawa,Hidehiko; Onitsuka,Takamitsu; Hanagiri,Takeshi; Tanaka,Fumihiro

doi:10.3892/etm.2011.258

Insulin-like growth factor receptor-1 expression predicts postoperative recurrence in adenocarcinoma of the lung

Authors:
- Makoto Nakagawa
- Hidetaka Uramoto
- Hidehiko Shimokawa
- Takamitsu Onitsuka
- Takeshi Hanagiri
- Fumihiro Tanaka
View Affiliations

Affiliations: Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
Published online on: April 26, 2011 https://doi.org/10.3892/etm.2011.258
Pages: 585-590

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Not all patients with lung cancer require post-operative adjuvant chemotherapy after a complete resection. However, no useful markers exist for either selecting appropriate candidates or for predicting clinical recurrence. The purpose of the present study was to clarify the clinical role of insulin-like growth factor receptor-1 (IGFR1) in lung adenocarcinoma. Tumor specimens were collected from 182 patients who underwent a complete resection for adenocarcinoma of the lung. The expression of IGFR1 was evaluated by immuno-histochemistry. The genetic status of the epidermal growth factor receptor (EGFR) and K-ras genes was also investigated by PCR-based analyses. Immunohistochemistry and real-time PCR assays were used to evaluate the MET gene association with tyrosine phosphorylation and hepatocyte growth factor (HGF) status, and amplification, respectively. Positive expression of IGFR1 was detected in 43 (23.6%) of the 182 cases. A positive IGFR1 expression was also identified in 12 (42.9%) and 31 (20.1%) of the patients with and without recurrence, respectively (p=0.009). Logistic regression models indicated that positive staining for IGFR1 expression was an independent factor associated with tumor recurrence. IGFR1 expression was associated with a poorer disease-free survival (DFS). Multivariate analysis demonstrated positive IGFR1 expression to be independently associated with an increased risk for poor DFS. The tumors appearing positive for IGFR1 were more frequent among those with K-ras mutations when compared with the wild-type group. IGFR1 expression was associated with reduced DFS correlating with postoperative recurrence. Therefore, the expression status of IGFR1 can be a candidate surrogate marker to select patients who may benefit from adjuvant chemotherapy.

View Figures

View References

1.	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
2.	Janssen-Heijnen ML and Coebergh JW: Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe. Lung Cancer. 31:123–137. 2001. View Article : Google Scholar : PubMed/NCBI
3.	Goya T, Asamura H, Yoshimura H, Kato H, Shimokata K, Tsuchiya R, Sohara Y, Miya T and Miyaoka E: The Japanese Joint Committee of Lung Cancer Registry Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer. 50:227–234. 2005. View Article : Google Scholar : PubMed/NCBI
4.	Pignon JP, Tribodet H, Scagliotti GV, et al: Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 26:3552–3559. 2008. View Article : Google Scholar : PubMed/NCBI
5.	Kato H, Ichinose Y and Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N and Ohta M: Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 350:1713–1721. 2004. View Article : Google Scholar : PubMed/NCBI
6.	Khandwala HM, McCutcheon IE, Flyvbjerg A and Friend KE: The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev. 21:215–244. 2000. View Article : Google Scholar : PubMed/NCBI
7.	LeRoith D and Roberts CT Jr: The insulin-like growth factor system and cancer. Cancer Lett. 195:127–137. 2003. View Article : Google Scholar : PubMed/NCBI
8.	Merrick DT, Dziadziuszko R, Szostakiewicz B, Szymanowska A, Rzyman W, Jassem E, Jassem J, Franklin WA, Bunn PA and Hirsch FR: High insulin-like growth factor 1 receptor (IGF 1R) expression is associated with poor survival in surgically treated non-small cell lung cancer (NSCLC) patients. J Clin Oncol. 25:75502007.
9.	Vallières E, Shepherd FA, Crowley J, van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z and Goldstraw P: International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 4:1049–1059. 2009.
10.	Onitsuka T, Uramoto H, Nose N, Takenoyama M, Hanagiri T, Sugio K and Yasumoto K: Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer. 68:198–203. 2010. View Article : Google Scholar : PubMed/NCBI
11.	Yamashita T, Uramoto H, Onitsuka T, Ono K, Baba T, So T, So T, Takenoyama M, Hanagiri T, Oyama T and Yasumoto K: Association between lymphangiogenesis-/micrometastasis- and adhesion-related molecules in resected stage I NSCLC. Lung Cancer. 70:320–328. 2010. View Article : Google Scholar
12.	Chang MH, Lee J, Han J, Park YH, Ahn JS, Park K and Ahn MJ: Prognostic role of insulin-like growth factor receptor-1 expression in small cell lung cancer. APMIS. 117:861–869. 2009. View Article : Google Scholar : PubMed/NCBI
13.	Onitsuka T, Uramoto H, Ono K, Takenoyama M, Hanagiri T, Oyama T, Izumi H, Kohno K and Yasumoto K: Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. J Thorac Oncol. 5:591–596. 2010.PubMed/NCBI
14.	Shimokawa H, Uramoto H, Onitsuka T, Iwata T, Nakagawa M, Ono K and Hanagiri T: TS expression predicts postoperative recurrence in adenocarcinoma of the lung. Lung Cancer. Oct. 21–2010, (E-pub ahead of print).
15.	Ludovini V, Bellezza G, Pistola L, et al: High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol. 20:842–849. 2009. View Article : Google Scholar : PubMed/NCBI
16.	Uramoto H, Sugio K, Oyama T, Ono K, Sugaya M, Yoshimatsu T, Hanagiri T, Morita M and Yasumoto K: Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. Lung Cancer. 51:71–77. 2006. View Article : Google Scholar : PubMed/NCBI
17.	Cappuzzo F, Toschi L, Tallini G, et al: Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann Oncol. 17:1120–1127. 2006. View Article : Google Scholar : PubMed/NCBI
18.	Karp DD, Paz-Ares LG, Novello S, et al: Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol. 27:2516–2522. 2009. View Article : Google Scholar
19.	Cappuzzo F, Tallini G, Finocchiaro G, et al: Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Ann Oncol. 21:562–567. 2010. View Article : Google Scholar : PubMed/NCBI
20.	Lee AV, Cui X and Oesterreich S: Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin Cancer Res. 7:4429–4435. 2001.PubMed/NCBI
21.	Gilmore AP, Valentijn AJ, Wang P, Ranger AM, Bundred N, O'Hare MJ, Wakeling A, Korsmeyer SJ and Streuli CH: Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem. 277:27643–27650. 2002. View Article : Google Scholar : PubMed/NCBI
22.	Shen YM, Yang XC, Yang C and Shen JK: Enhanced therapeutic effects for human pancreatic cancer by application K-ras and IGF-IR antisense oligodeoxynucleotides. World J Gastroenterol. 14:5176–5185. 2008. View Article : Google Scholar : PubMed/NCBI
23.	Scartozzi M, Mandolesi A, Giampieri R, et al: Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild-type colorectal cancer patients treated with cetuximab and irinotecan. Int J Cancer. 127:1941–1947. 2010. View Article : Google Scholar